|
|
Hiroshi Takayanagi, Takuo Juji, Tsuyoshi Miyazaki, Hideharu Iizuka, Tokiharu Takahashi, Masashi Isshiki, Masato Okada, Yoshiya Tanaka, Yasuko Koshihara, Hiromi Oda, Takahide Kurokawa, Kozo Nakamura, Sakae Tanaka
J Clin Invest. 1999;
104(2):137
doi:10.1172/JCI6093
Abstract |
Full text
| PDF

R
heumatoid arthritis (RA) is characterized by a chronic inflammation of the synovial joints resulting from hyperplasia of synovial fibroblasts and infiltration of lymphocytes, macrophages, and plasma cells, all of which manifest signs of activation. Recent studies have revealed the essential role of osteoclasts in joint destruction in RA. Src family tyrosine kinases are implicated in various intracellular signaling pathways, including mitogenic response to growth factors in fibroblasts, activation of lymphocytes, and osteoclastic bone resorption. Therefore, inhibiting Src activity can be a good therapeutic strategy to prevent joint inflammation and destruction in RA. We constructed an adenovirus vector carrying the csk gene, which negatively regulates Src family tyrosine kinases. Csk overexpression in cultured rheumatoid synoviocytes remarkably suppressed Src kinase activity and reduced their proliferation rate and IL-6 production. Bone-resorbing activity of osteoclasts was strongly inhibited by Csk overexpression. Furthermore, local injection of the virus into rat ankle joints with adjuvant arthritis not only ameliorated inflammation but suppressed bone destruction. In conclusion, adenovirus-mediated direct transfer of the csk gene is useful in repressing bone destruction and inflammatory reactions, suggesting the involvement of Src family tyrosine kinases in arthritic joint breakdown and demonstrating the feasibility of intervention in the kinases for gene therapy in RA.J. Clin. Invest. 104:137–146 (1999).
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
About CrossRef
| Title and authors |
Publication |
Year |
. |
Osteoclasts and Interleukin-17-Producing Helper T Cells in Rheumatoid
Kazuo Okamoto, Hiroshi Takayanagi |
Arthritis Pathophysiology Prevention and Therapeutics |
2011 |
.
|
The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells
Anja Huq, Baljit Singh, Thea Meeker, Desmond Mascarenhas |
Anti-Cancer Drugs |
2009 |
.
|
Tyrosine kinases as targets for the treatment of rheumatoid arthritis
Christina D'Aura Swanson, Ricardo T. Paniagua, Tamsin M. Lindstrom, William H. Robinson |
Nat Rev Rheumatol |
2009 |
.
|
Osteoimmunology: Crosstalk Between the Immune and Bone Systems
Tomoki Nakashima, Hiroshi Takayanagi |
J Clin Immun |
2009 |
.
|
Effects of the Sri Lankan medicinal plant, Salacia reticulata, in rheumatoid arthritis
Yuusuke Sekiguchi, Hiroshi Mano, Sachie Nakatani, Jun Shimizu, Masahiro Wada |
Genes Nutr |
2009 |
.
|
Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis
Omer Kutlu, Erdem Akkaya, Ismail Turker Koksal, Ibrahim Cumhur Bassorgun, Mehmet Akif Ciftcioglu, Salih Sanlioglu, Erdal Kukul |
Int Urol Nephrol |
2009 |
.
|
Osteoclasts and the immune system
Tomoki Nakashima, Hiroshi Takayanagi |
J Bone Min Metab |
2009 |
.
|
Tumor necrosis factor-α inhibits chondrogenic differentiation of synovial fibroblasts through p38 mitogen activating protein kinase pathways
Chiaki Okuma-Yoshioka, Hiroaki Seto, Yuho Kadono, Atsuhiko Hikita, Yasushi Oshima, Hisashi Kurosawa, Kozo Nakamura, Sakae Tanaka |
Mod Rheumatol |
2008 |
.
|
Gene therapy for arthritis
Russell S. Traister, Raphael Hirsch |
Mod Rheumatol |
2008 |
.
|
Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis
Ayako Suematsu, Yasuhito Tajiri, Tomoki Nakashima, Junko Taka, Sae Ochi, Hiromi Oda, Kozo Nakamura, Sakae Tanaka, Hiroshi Takayanagi |
Mod Rheumatol |
2007 |
.
|
Transplantation of skin fibroblasts expressing BMP-2 contributes to the healing of critical-sized bone defects
Kazunari Hirata, Akio Mizuno, Akira Yamaguchi |
J Bone Min Metab |
2007 |
.
|
Interplay between the immune and skeletal cells in the regulation of inflammatory bone destruction
Ayako SUEMATSU, Hiroshi TAKAYANAGI |
Jpn J Clin Immunol |
2007 |
.
|
Molecular mechanism of bone destruction in rheumatoid arthritis
Tsuyoshi Miyazaki, Seizo Yamamoto, Sakae Tanaka |
Future Rheumatology |
2007 |
.
|
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Hiroshi Takayanagi |
Nature Review Immunology |
2007 |
.
|
Osteoclasts, rheumatoid arthritis, and osteoimmunology
Kojiro Sato, Hiroshi Takayanagi |
Current Opinion in Rheumatology |
2006 |
.
|
Critical role of cortactin in actin ring formation and osteoclastic bone resorption
Takuma Matsubara, Akira Myoui, Fumiyo Ikeda, Kenji Hata, Hideki Yoshikawa, Riko Nishimura, Toshiyuki Yoneda |
J Bone Min Metab |
2006 |
.
|
In vitro and in vivo assays for osteoclast apoptosis
Toru Akiyama, Tsuyoshi Miyazaki, Phillippe Bouillet, Kozo Nakamura, Andreas Strasser, Sakae Tanaka |
Biol Proced Online |
2005 |
.
|
Recent advances in the discovery of Src kinase inhibitors
Keykavous Parang, Gongqin Sun |
eotp |
2005 |
.
|
Interplay between interferon and other cytokine systems in bone metabolism
Hiroshi Takayanagi, Kojiro Sato, Akinori Takaoka, Tadatsugu Taniguchi |
Immunol Rev |
2005 |
.
|
Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo
Eijiro Jimi, Kazuhiro Aoki, Hiroaki Saito, Fulvio D'Acquisto, Michael J May, Ichiro Nakamura, Testuo Sudo, Takefumi Kojima, Fujio Okamoto, Hidefumi Fukushima, Koji Okabe, Keiichi Ohya, Sankar Ghosh |
Nat Med |
2004 |
.
|
|
|
|